PULMONOLOGISTS REPORT HIGH UNMET NEED FOR NEW PRODUCTS TO TREAT IDIOPATHIC PULMONARY FIBROSIS (IPF), DESPITE THE RECENT LAUNCHES OF ROCHE’S ESBRIET AND BOEHINGER INGELHEIM’S OFEV
Roughly half of surveyed pulmonologists treating patients with IPF have concerns about tolerability and side effects with currently available options, according to Spherix Global Insights, GmbH Nov 30, 2015 – Zug, Switzerland – Feedback gathered from the recently released Market…